Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease - A possible target for infliximab treatment

European Journal of Gastroenterology and Hepatology

Volumn 16, Issue 7, 2004, Pages 649-655

  Agnholt, Jørgen ^a   Kelsen, Jens ^a   Brandsborg, Birgitte ^a   Jakobsen, Niels O ^a   Dahlerup, Jens F ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Crohn's disease; Cytokines; GM CSF; Inflammation; Neutrophils

Indexed keywords

ANTIGEN; C REACTIVE PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INFLIXIMAB; INTERLEUKIN 2; INTERLEUKIN 4;

ADULT; ARTICLE; CLINICAL ARTICLE; COLON BIOPSY; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG TARGETING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL CULTURE; HUMAN TISSUE; INTESTINE CELL; LEUKOCYTE COUNT; MALE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; T LYMPHOCYTE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; CELLS, CULTURED; COLON; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOPHENOTYPING; INTESTINAL MUCOSA; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTE SUBSETS;

EID: 3142588819     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.meg.0000108344.41221.8b     Document Type: Article

References (29)

1. Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 1997; 92:5S-11S.
2. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115:182-205.
3. Panja A, Goldberg S, Eckmann L, Krishen P, Mayer L. The regulation and functional consequence of proinflammatory cytokine binding on human intestinal epithelial cells. J Immunol 1998; 161:3675-3684.
4. Geboes K, Dalle I. Influence of treatment on morphological features of mucosal inflammation. Gut 2002; 50:37-42.
5. Goldman H. Interpretation of large intestinal mucosal biopsy specimens. Human Pathology 1994; 25:1150-1159.
6. Stahlberg D, Veress B, Mare K, Granqvist S, Agren B, Richter S, et al. Leukocyte migration in acute colonic inflammatory bowel disease: Comparison of histological assessment and Tc-99m-HMPAO labeled leukocyte scan. Am J Gastroenterol 1997; 92:283-288.
7. Griffin JD, Spertini O, Ernst TJ, Belvin MP, Levine HB, Kanakura Y, et al. Granulocyte-macrophage colony-stimulating factor and other cytokines regulate surface expression of the leukocyte adhesion molecule-1 on human neutrophils, monocytes, and their precursors. J Immunol 1990; 145:576-584.
8. Ina K, Kusugami K, Hosokawa T, Imada A, Shimizu T, Yamaguchi T, et al. Increased mucosal production of granulocyte colony-stimulating factor is related to a delay in neutrophil apoptosis in inflammatory bowel disease. J Gastroenterol Hepatol 1999; 14:46-53.
9. Zavala F, Masson A, Hadaya K, Ezine S, Schneider E, Babin O, et al. Granulocyte-colony-stimulating factor treatment of lupus autoimmune disease in MRL-Ipr/Ipr mice. J Immunol 1999; 163:5125-5132.
10. Dieckgraefe BK, Korzenik JR. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet 2002; 360:1478-1480.
11. Landi B, Nguyen T, Cortot A, Soule JC, Rene E, Gendre JP, et al. Endoscopic monitoring of Crohn's disease treatment - a prospective, randomized clinical trial. Gastroenterology 1992; 102:1647-1653.
12. Olaison G, Sjodahl R, Tagesson C. Glucocorticoid treatment in ileal Crohn's disease - relief of symptoms but not of endoscopically viewed inflammation. Gut 1990; 31:325-328.
13. Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999; 116:22-28.
14. D'Haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multi-center trial. Gastroenterology 1999; 116:1029-1034.
15. ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002; 50:206-211.
16. Waetzig GH, Seegert D, Rosenstiel P, Nikolaus S, Schreiber S. p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J Immunol 2002; 168: 5342-5351.
17. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70:439-444.
18. D'Haens GR, Geboes K, Peeters M, Baert F, Pennickx F, Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998; 114:262-267.
19. Agnholt J, Kaltoft K. In situ activated intestinal T cells expanded in vitro - without addition of antigen - produce IFN-gamma and IL-10 and preserve their function during growth. Exp Clin Immunogenet 2001; 18:213-225.
20. Noguchi M, Hiwatashi N, Liu ZX, Toyota T. Increased secretion of granulocyte-macrophage colony-stimulating factor in mucosal lesions of inflammatory bowel disease. Digestion 2001; 63:32-36.
21. Rogler G, Gelbmann CM, Vogl D, Brunner M, Scholmerich J, Falk W, et al. Differential activation of cytokine secretion in primary human colonic fibroblast/myofibroblast cultures. Scand J Gastroenterol 2001; 36: 389-398.
22. Carlson M, Raab Y, Peterson C, Hallgren R, Venge P. Increased intraluminal release of eosinophil granule proteins EPO, ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion. Am J Gastroenterol 1999; 94:1876-1883.
23. Carlson M, Raab Y, Seveus L, Xu S, Hallgren R, Venge P. Human neutrophil lipocalin is a unique marker of neutrophil inflammation in ulcerative colitis and proctitis. Gut 2002; 50:501-506.
24. Heystek HC, Mudde GC, Ohler R, Kalthoff FS. Granulocyte-macrophage colony-stimulating factor (GM-CSF) has opposing effects on the capacity of monocytes versus monocyte-derived dendritic cells to stimulate the antigen-specific proliferation of a human T cell clone. Clin Exp Immunol 2000; 120:440-447.
25. Ikeda Y, Akbar SM, Matsui H, Onji M. Antigen-presenting dendritic cells in ulcerative colitis. J Gastroenterol 2002; 37 (suppl 14):53-55,
26. Bregenholt S, Claesson MH. Splenic T helper cell type 1 cytokine profile and extramedullary haematopoiesis in severe combined immunodeficient (scid) mice with inflammatory bowel disease (IBD). Clin Exp Immunol 1998; 111:166-172.
27. Agnholt J, Kaltoft K. Infliximab downregulates interferon-gamma production in activated gut T lymphocytes from patients with Crohn's disease. Cytokine 2001; 15:212-222.
28. Nikolaus S, Bauditz J, Gionchetti P, Witt C, Lochs H, Schreiber S. Increased secretion of pro-inflammatory cytokines by circulating polymor-phonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation. Gut 1998; 42:470-476.
29. Shimoyama T, Sawada K, Hiwatashi N, Sawada T, Matsueda K, Munakata A, et al. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apheresis 2001; 16:1-9.